Molecular Mechanisms of Thyroid Hormone Transport by l-Type Amino Acid Transporter

Abstract

Thyroid hormones (TH) pass through the plasma membrane into the target cells via transporter proteins. Thyroid hormone transporters that have been identified until now belong to two different solute carrier (SLC) subfamilies i) the major facilitator superfamily (MFS) and ii) the amino acid polyamine-organocation (APC) superfamily. Both are comprised by 12 transmembrane helices, however with different structural topology. The TH transporter MCT8, MCT10 and OATP1C1 are members of the MSF. The l-type amino acid transporters (LATs) are transporting neutral amino acids across the membrane. Two LAT subtypes, LAT1 and LAT2 are members of the APC superfamily, need the escort protein 4F2hc and facilitate uptake but no efflux of TH-subtypes. Homology models of LAT2 that are based on crystal structures of APC transporters guided mutagenesis, revealed molecular structure-function determinants for recognition and transition for import and export of TH-subtypes. The recently solved cryo-EM structure of LAT1 confirmed the structural input. Two other LAT subtypes, LAT3 and LAT4 are members of the MFS. From previous observed negative effect of LAT3 and LAT4 on 3,3’-T2 uptake by LAT1 and LAT2 it was indirectly concluded that LAT3 might export 3,3’-T2. There are still open questions that need to be addressed in order to fully understand the molecular recognition pattern and traversing mechanism of import and export of particular TH-subtypes by LAT1 and LAT2. Moreover, clarification is needed whether LAT3 and LAT4 are exporting TH. Recent new data could not verify the initial hypothesis of TH export by LAT3. Therefore, further investigations are necessary to explain the negative effect of LAT3 on the TH import by LAT2.

Key words

autoimmunity - thyroid - hormones - signal transduction - receptors - thyrotropin - obesity - melanocortin receptors - thyroid hormone transporters - l-type amino acid transporter - uptake/efflux - alimentation - cancer - vitamines - thyroiditis - lymphoma - graves- disease - polycystic ovary syndrome

Publication History

Received: 29 August 2019
Received: 17 October 2019

Accepted: 21 October 2019

Article published online:
18 November 2019

• References

• 1 Hennemann G, Docter R, Friesema EC. et al. Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability. Endoc Rev 2001; 22: 451-476
• 2 Wirth EK, Schweizer U, Köhrle J. Transport of thyroid hormone in brain. Front Endocrinol 2014; 5: 1-7
• 3 Müller J, Heuer H. Expression pattern of thyroid hormone transporters in the postnatal mouse brain. Front Endocrinol 2014; 5: 92
• 4 Friesema EC, Ganguly S, Abdalla A. et al. Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. J Biol Chem 2003; 278: 40128-40135
• 5 Friesema EC, Jansen J, Jachtenberg JW et al. Effective cellular uptake and efflux of thyroid hormone by human monocarboxylate transporter 10. Mol Endocrinol (Baltimore, Md.). 2008: 22: 1357–1369
• 6 Friesema EC, Docter R, Moerings EP. et al. Thyroid hormone transport by the heterodimeric human system L amino acid transporter. Endocrinology 2001; 142: 4339-4348
• 7 Braun D, Kinne A, Brauer A. et al. Developmental and cell type-specific expression of thyroid hormone transporters in the mouse brain and in primary brain cells. Glia 2011; 59: 463-471
• 8 Wirth EK, Roth A, Blechschmidt C. et al. Neuronal 3’,3,5-triiodothyronine (T3) uptake and behavioral phenotype of mice deficient in Mct8, the neuronal T3 transporter mutated in Allan-Herndon-Dudley syndrome. J Neurosci 2009; 29: 9439-9449
• 9 Protze J, Braun D, Hinz KM. et al. Membrane-traversing mechanism of thyroid hormone transport by monocarboxylate transporter 8. Cell Mol Life Sci 2017; 74: 2299-2318
• 10 Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev 1990; 70: 43-77
• 11 Jonas W, Lietzow J, Wohlgemuth F. et al. 3,5-Diiodo-l-thyronine (3,5-T2) Exerts thyromimetic effects on hypothalamus-pituitary-thyroid axis, body composition, and energy metabolism in male diet-induced obese mice. Endocrinology 2015; 156: 389-399
• 12 Lehmphul I, Brabant G, Wallaschofski H. et al. Detection of 3,5-Diiodothyronine in sera of patients with altered thyroid status using a new monoclonal antibody-based chemiluminescence immunoassay. Thyroid 2014; 24: 1350-1360
• 13 Lanni A, Moreno M, Horst C. et al. Specific binding sites for 3,3’-diiodo-l-thyronine (3,3’-T2) in rat liver mitochondria. FEBS Lett 1994; 351: 237-240
• 14 Mendoza A, Navarrete-Ramirez P, Hernandez-Puga G. et al. 3,5-T2 Is an alternative ligand for the thyroid hormone receptor beta 1. Endocrinology 2013; 154: 2948-2958
• 15 Meier C, Ristic Z, Verrey E. et al. Activation of system L heterodimeric amino acid exchangers by intracellular substrates. EMBO J 2002; 21: 580-589
• 16 Boado RJ, Li JY, Chu C. et al. Site-directed mutagenesis of cysteine residues of large neutral amino acid transporter LAT1. Biochim Biophys Acta 2005; 1715: 104-110
• 17 Dickens D, Webb S, Antonyuk S. et al. Transport of gabapentin by LAT1 (SLC7A5). Biochem Pharmacol 2013; 85: 1672-1683
• 18
• 19 Morimoto E, Kanai Y, Kim D. et al. Establishment and characterization of mammalian cell lines stably expressing human l-type amino acid transporters. J Pharmacol Sci 2008; 108: 505-516
• 20 Khunweeraphong N, Nagamori S, Wiriyasermkul P. et al. Establishment of stable cell lines with high expression of heterodimers of human 4F2hc and human amino acid transporter LAT1 or LAT2 and delineation of their differential interaction with alpha;-Alkyl moieties. J Pharmacol Sci 2012; 119: 368-380
• 21 Segawa H, Fukasawa Y, Miyamoto K. et al. Identification and functional characterization of a na – independent neutral amino acid transporter with broad substrate selectivity. J Biol Chem 1999; 274: 19745-19751
• 22 Pineda M, Fernàndez E, Torrents D. et al. Identification of a membrane protein, LAT-2, that Co-expresses with 4F2 heavy chain, an l-type amino acid transport activity with broad specificity for small and large zwitterionic amino acids. J Biol Chem 1999; 274: 19738-19744
• 23 Kinne A, Wittner M, Wirth EK. et al. Involvement of the l-Type amino acid transporter LAT2 in the transport of 3,3’-Diiodothyronine across the plasma membrane. Eur Thyroid J 2015; 4: 42-50
• 24 Gao X, Lu F, Zhou L. et al. Structure and mechanism of an amino acid antiporter. Science 2009; 324: 1565-1568
• 25 Shaffer PL, Goehring A, Shankaranarayanan A. et al. Structure and mechanism of a Na+-independent amino acid transporter. Science 2009; 325: 1010-1014
• 26 Krause G, Hinz KM. Thyroid hormone transport across l-type amino acid transporters: What can molecular modelling tell us?. Mol Cell Endocrinol 2017; 458: 68-75
• 27 Yan R, Zhao X, Lei J. et al. Structure of the human LAT1–4F2hc heteromeric amino acid transporter complex. Nature 2019; 568: 127-130
• 28 Hinz KM, Neef D, Rutz C. et al. Molecular features of the l-type amino acid transporter 2 determine different import and export profiles for thyroid hormones and amino acids. Mol Cell Endocrinol 2017; 443: 163-174
• 29 Zevenbergen C, Meima ME, Peeters RP. et al. Transport of iodothyronines by human l-type amino acid transporters. Endocrinology 2015; 156: 4345-4355
• 30 Teichmann A, Rutz C, Kreuchwig A. et al. The pseudo signal peptide of the corticotropin-releasing factor receptor type 2A prevents receptor oligomerization. J Biol Chem 2012; 287: 27265-27274